The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
Abstract
Purpose: The aims of this study were to identify the most significant prognostic factors in myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and their changes in time and to develop a dynamic model for predicting survival and leukemic evolution that can be applied at any time during the course of the disease. Patients and Methods: We studied a learning cohort of 426 MDS patients diagnosed at the Department of Hematology, San Matteo Hospital, Pavia, Italy, between 1992 and 2004, and a validation cohort of 739 patients diagnosed at the Heinrich-Heine-University Hospital, Düsseldorf, Germany, between 1982 and 2003. All patients were reclassified according to WHO criteria. Univariable and multivariable analyses were performed using Cox models with time-dependent covariates. Results: The most important variables for the prognostic model were WHO subgroups, karyotype, and transfusion requirement. We defined a WHO classification–based prognostic scoring system (WPSS) that was able to classify patients into five risk groups showing different survivals (median survival from 12 to 103 months) and probabilities of leukemic evolution (P < .001). WPSS was shown to predict survival and leukemia progression at any time during follow-up (P < .001), and its prognostic value was confirmed in the validation cohort. Conclusion: WPSS is a dynamic prognostic scoring system that provides an accurate prediction of survival and risk of leukemic evolution in MDS patients at any time during the course of their disease. This time-dependent system seems particularly useful in lower risk patients and may be used for implementing risk-adapted treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationProposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Self-citationMyelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
Sanz, G., Sanz, M., Vallespi, T., Canizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & San Miguel, J. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Myelodysplastic Syndromes — Coping with Ineffective Hematopoiesis
Cazzola, M., & Malcovati, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048266 · Cited by 343
Self-citationGuidelines for the diagnosis and therapy of adult myelodysplastic syndromes
Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., Parker, J., & of the UK MDS Guidelines Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03907.x · Cited by 298
Germing, U., Gattermann, N., Strupp, C., Aivado, M., & Aul, C. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00088-6 · Cited by 296
Self-citation
Cited by
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Self-citationClinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 670
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Self-citationLuspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Cazzola, M., Ilhan, O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908892 · Cited by 550
Self-citationMalcovati, L., Papaemmanuil, E., Bowen, D. T., Boultwood, J., Della Porta, M. G., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 498
Self-citationFenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., te Boekhorst, P., Sanz, G., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 486
Self-citationKantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J. M., List, A., Fenaux, P., Sanz, G., Issa, J., et al. (2008) · Cancer · doi:10.1002/cncr.23697 · Cited by 482
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434
Self-citationLandscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes
Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Shiozawa, Y., Kon, A., Alpermann, T., Yoshida, K., et al. (2013) · Blood · doi:10.1182/blood.v122.21.521.521 · Cited by 431
(2013) · doi:10.1158/2159-8290.cd-13-0350 · Cited by 393
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Elena, C., Gallì, A., Such, E., Meggendorfer, M., Germing, U., Rizzo, E., Cervera, J., Molteni, E., Fasan, A., Schuler, E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-714030 · Cited by 361
Self-citationMufti, G. J., Bennett, J. M., Goasguen, J., Bain, B. J., Baumann, I., Brunning, R., Cazzola, M., Fenaux, P., Germing, U., Hellstrom-Lindberg, E., et al. (2008) · Haematologica · doi:10.3324/haematol.13405 · Cited by 339
Self-citationNimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 336
Such, E., Germing, U., Malcovati, L., Cervera, J., Kuendgen, A., Della Porta, M. G., Nomdedeu, B., Arenillas, L., Luño, E., Xicoy, B., et al. (2013) · Blood · doi:10.1182/blood-2012-08-452938 · Cited by 316
Self-citationJädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4906 · Cited by 300
Self-citationGreenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0005 · Cited by 290
Goldberg, S. L., Chen, E., Corral, M., Guo, A., Mody-Patel, N., Pecora, A. L., & Laouri, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2395 · Cited by 289
Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., Ades, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8652 · Cited by 284
Self-citationMalcovati, L., Della Porta, M. G., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044602 · Cited by 282
Self-citationTET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276
Lyons, R. M., Cosgriff, T. M., Modi, S. S., Gersh, R. H., Hainsworth, J. D., Cohn, A. L., McIntyre, H. J., Fernando, I. J., Backstrom, J. T., & Beach, C. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1058 · Cited by 274
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Such, E., Cervera, J., Costa, D., Sole, F., Vallespi, T., Luno, E., Collado, R., Calasanz, M. J., Hernandez-Rivas, J. M., Cigudosa, J. C., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030957 · Cited by 269
Della Porta, M. G., Malcovati, L., Boveri, E., Travaglino, E., Pietra, D., Pascutto, C., Passamonti, F., Invernizzi, R., Castello, A., Magrini, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2246 · Cited by 254
Self-citationDella Porta, M. G., Gallì, A., Bacigalupo, A., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., van Lint, M. T., Pioltelli, P., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 254
Self-citationSekeres, M. A., Schoonen, W. M., Kantarjian, H., List, A., Fryzek, J., Paquette, R., & Maciejewski, J. P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn349 · Cited by 248
Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments
Leitch, H. A. (2011) · Drugs · doi:10.2165/11585280-000000000-00000 · Cited by 17
Metadata
- Authors
- Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., Strupp, C., Lazzarino, M., Aul, C., & Cazzola, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-08-10
- Volume
- 25
- Issue
- 23
- Pages
- 3503-3510
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148968593
- Cited by
- 1,032
- References
- 26
- FWCI
- 45.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.